Hong Kong (01 August 2006) - Advantek Biologics Limited announced through its exclusive distributor Worldbridge Phils Inc. that the Philippines Bureau of Food and Drugs (BFAD) had accepted its application for the initial registration of Advantek and its supplier, Shanghai Xinxing Medicines Co. Ltd.'s Human Immunoglobulin, a 2.5 gram of 50 ml vial, solution for intravenous injection.

It is estimated that the registration may take 1 year or so. Advantek is also preparing such registration applications in other countries throughout the region. Approval in the Philippines will provide the company an opportunity to gain market share in the country and also drive other business opportunities in the South East Asia market as well.

Advantek Biologics Limited is engaged in the R&D, commercialization, manufacture, marketing and sale of plasma-derived therapeutics, and biochemicals. Advantek is the first and only Hong Kong-based biopharmaceutical manufacturer. To reflect a mission of bringing safe biopharmaceuticals to patients in need, particularly those living in developing countries, Advantek has adopted "Saving Lives Through Safe Biologics" as corporate motto.

Disclaimer: The content of this news release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. Statements in this news release that are not strictly historical may be forward-looking statements. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties. The parties undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. The parties believe that contents of this press release are accurate and however, make no representations or warranties about the completeness or the accuracy or any other matter.